Evidence map›Paper›PMID 32459885›Full record

Trial reportClinical pharmacology in drug development2021

Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study.

Masahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, Akihisa Nishimura, Nobutaka Hattori

Open access · hybridAbstract readClinical Trial, Phase IComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.Movement disorders : official journal of the Movement Disorder Society · 2021
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Masahiro NomotoDepartment of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Atsushi TakedaNational Hospital Organization, Sendai-Nishitaga Hospital, Sendai, Japan.
Katsuaki IwaiDepartment of Clinical Development, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Akihisa NishimuraDepartment of Clinical Development, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Nobutaka HattoriDepartment of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ono Pharmaceutical (Japan) · JPEhime University · JPJuntendo University · JPSendai Nishitaga National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opicapone, a peripheral, long-acting catechol-O-methyltransferase inhibitor has been shown to improve wearing-off phenomenon in randomized, double-blind studies. This study compared the pharmacokinetic characteristics of opicapone small-tablet and size 1 capsule formulations after single oral administration to healthy Japanese subjects. In this open-label, randomized, 2-way and 2-period crossover phase 1 study, 48 healthy male subjects (aged 20 to 45 years; body mass index, 18.5 to <30.0 kg/m

Indexed as

Administration, OralAdultArea Under CurveAsian PeopleCapsulesCatechol O-Methyltransferase InhibitorsCross-Over StudiesDose-Response Relationship, DrugHalf-LifeHumansMaleMiddle AgedOxadiazolesTabletsYoung AdultCapsulesCatechol O-Methyltransferase InhibitorsopicaponeOxadiazolesTabletsCOMT inhibitorJapaneseopicaponeParkinson's diseasepharmacokineticphase 1

Identifiers

PMID32459885
PMCPMC7891373
OpenAlexW3029494517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.